The long-term objective of this proposal is to structurally define type II topoisomerase function and drug inhibition mechanisms. Type II topoisomerases are a ubiquitous class of proteins that use ATP to actively transport one DNA duplex through another. This reaction maintains appropriate levels of DNA supercoiling and resolves lethal chromosome tangles in the cell. Eukaryotic type II topoisomerases are also exploited by certain inhibitors that are frontline clinical therapies for cancer. The focus of this proposal is on eukaryotic topoisomerase II and archaeal topoisomerase VI, two representative members of type IIA and liB topoisomerases, respectively.
The specific aims of the research are as follows: 1. To understand how type II topoisomerases physically switch between conformational states. 2. To define how type II topoisomerases interact with and utilize reaction substrates. 3. To determine how certain anticancer agents bind to and inhibit eukaryotic topoisomerase II Although a general framework exists for understanding type II topoisomerase function, significant gaps remain. A detailed structural description of type II topoisomerase mechanism coupled with biochemical validation, will illuminate critical aspects of these enzymes' function. The studies outlined here will define the physical events by which type II topoisomerases catalyze the ATP-dependent passage of one DNA segment through another and by which anticancer inhibitors subvert enzyme function. Data resulting from such efforts broadly impact a number of important scientific research fronts, from understanding how a molecular machine maintains chromosome topology to dissecting the molecular basis of various chemotherapeutic treatments.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA077373-06
Application #
6731274
Study Section
Biochemistry Study Section (BIO)
Program Officer
Knowlton, John R
Project Start
1999-05-01
Project End
2009-02-28
Budget Start
2004-03-01
Budget End
2005-02-28
Support Year
6
Fiscal Year
2004
Total Cost
$293,205
Indirect Cost
Name
University of California Berkeley
Department
Biochemistry
Type
Schools of Arts and Sciences
DUNS #
124726725
City
Berkeley
State
CA
Country
United States
Zip Code
94704
Wendorff, Timothy J; Berger, James M (2018) Topoisomerase VI senses and exploits both DNA crossings and bends to facilitate strand passage. Elife 7:
Lee, Joyce H; Wendorff, Timothy J; Berger, James M (2017) Resveratrol: A novel type of topoisomerase II inhibitor. J Biol Chem 292:21011-21022
Nodelman, Ilana M; Bleichert, Franziska; Patel, Ashok et al. (2017) Interdomain Communication of the Chd1 Chromatin Remodeler across the DNA Gyres of the Nucleosome. Mol Cell 65:447-459.e6
Ashley, Rachel E; Blower, Tim R; Berger, James M et al. (2017) Recognition of DNA Supercoil Geometry by Mycobacterium tuberculosis Gyrase. Biochemistry 56:5440-5448
Blower, Tim R; Williamson, Benjamin H; Kerns, Robert J et al. (2016) Crystal structure and stability of gyrase-fluoroquinolone cleaved complexes from Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 113:1706-13
Hauk, Glenn; Berger, James M (2016) The role of ATP-dependent machines in regulating genome topology. Curr Opin Struct Biol 36:85-96
Aldred, Katie J; Blower, Tim R; Kerns, Robert J et al. (2016) Fluoroquinolone interactions with Mycobacterium tuberculosis gyrase: Enhancing drug activity against wild-type and resistant gyrase. Proc Natl Acad Sci U S A 113:E839-46
Drlica, Karl; Mustaev, Arkady; Towle, Tyrell R et al. (2014) Bypassing fluoroquinolone resistance with quinazolinediones: studies of drug-gyrase-DNA complexes having implications for drug design. ACS Chem Biol 9:2895-904
Kranzusch, Philip J; Lee, Amy S Y; Wilson, Stephen C et al. (2014) Structure-guided reprogramming of human cGAS dinucleotide linkage specificity. Cell 158:1011-1021
Vos, Seychelle M; Lyubimov, Artem Y; Hershey, David M et al. (2014) Direct control of type IIA topoisomerase activity by a chromosomally encoded regulatory protein. Genes Dev 28:1485-97

Showing the most recent 10 out of 49 publications